INmune Bio
INMB
INMB
35 hedge funds and large institutions have $17.4M invested in INmune Bio in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
9% less capital invested
Capital invested by funds: $19.1M → $17.4M (-$1.73M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Holders
35
Holding in Top 10
–
Calls
$645K
Puts
$413K
Top Buyers
| 1 | +$284K | |
| 2 | +$194K | |
| 3 | +$133K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$94.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$84.2K |
Top Sellers
| 1 | -$815K | |
| 2 | -$619K | |
| 3 | -$568K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$438K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$404K |